|
|
Exopharm Limited is an Australia-based company, which is engaged in transformative medicines using exosomes or extracellular vesicles (EVs) and is also engaged in product pipeline-driven platform strategy. The Company's principal activities include pipeline products analysis and selection; technology development and validation; and commercial collaborations. The Company operates through regenerative medicine and biopharmaceutical drug development segment. Its exosome technologies solve the needs for the success of exosome medicines. Its technologies include LEAP manufacturing technology, LOAD active pharmaceutical ingredients (APIs) loading technologies, and EVPS tropism technologies. The Company is developing Engineered EVs (EEVs), an emerging form of precision medicine with application in areas, such as neurology, cardiology, and oncology. Its EEV technology includes EVPS to provide tissue tropism to exosomes and LOAD to load in APIs, such as messenger ribonucleic acid (mRNA).
Number of employees : 41 people.
|
|
|
| Vote  | Quantity | Free-Float | Company-owned shares | Total Float |
| Stock A |
1 |
157,211,533 |
91,057,254 |
57.9% |
0 |
0.0% |
57.9% |
|
|
|
| Name | Equities | % | | Altnia Holdings Pty Ltd. | 28,258,627 |
18.0% | | Carl Charalambous | 13,786,272 |
8.77% | | Kohen Enterprises Pty Ltd. | 2,002,000 |
1.27% | | Paul Joseph Cozzi | 2,000,000 |
1.27% | | Michael Francis Mcmahon | 1,635,849 |
1.04% | | Oldview Agriculture Pvt Ltd. | 1,610,000 |
1.02% | | Development Management & Consulting Group, Inc. | 1,545,350 |
0.98% | | Russell Neil Creagh | 1,457,000 |
0.93% | | Peter Dallas Checkley | 1,410,275 |
0.90% | | Norman Cipriano | 1,312,500 |
0.83% |
|
| Company contact information |
|
Exopharm Ltd. Level 17/31 Queen Street Melbourne, Victoria (VIC) 3000 Phone : +61.3.9111.0026 Web : http://www.exopharm.com |
|
|
Sector Other Biotechnology & Medical Research
| | 1st jan. | Capi. (M$) |
 | EXOPHARM LIMITED | -66.35% | 20 |
| | | |
 | MODERNA, INC. | -45.70% | 54 855 |
 | LONZA GROUP AG | -27.63% | 40 862 |
| IQVIA HOLDINGS INC. | -26.03% | 39 504 |
| SEAGEN INC. | -12.27% | 24 966 |
| ICON PUBLIC LIMITED COMPANY | -31.87% | 17 153 |
 | CELLTRION, INC. | -26.77% | 15 702 |
| ALNYLAM PHARMACEUTICALS, INC. | -25.42% | 15 279 |
| BIO-TECHNE CORPORATION | -28.91% | 14 449 |
 | PHARMARON BEIJING CO., LTD. | -18.86% | 12 633 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | -37.41% | 11 980 |
| HANGZHOU TIGERMED CONSULTING CO., LTD | -30.83% | 10 833 |
| QIAGEN N.V. | -17.00% | 10 492 |
| BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | 2.31% | 10 017 |
| UNITED THERAPEUTICS CORPORATION | -15.11% | 8 310 |
| SYNEOS HEALTH, INC. | -31.72% | 7 192 |
| AZENTA, INC. | -27.15% | 5 583 |
| BACHEM HOLDING AG | 0.00% | 5 420 |
 | GENSCRIPT BIOTECH CORPORATION | -42.49% | 5 317 |
| IONIS PHARMACEUTICALS, INC. | 18.57% | 5 116 |
| JOINN LABORATORIES (CHINA) CO.,LTD. | -14.17% | 5 099 |
Connections : Exopharm Limited |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
